Drug Trial Radar · NCT05433584
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
794
Actual
Start
Aug 1, 2022
Primary completion
Oct 21, 2025
Study completion Nov 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jun 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
Conditions
- Type 2 Diabetes
Interventions
TirzepatideDrug
Administered SC
Antihyperglycemic medicationDrug
As prescribed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline, Week 104
Locations
90 sites in 11 countries. Site status is shown where the registry gives one.
Cahaba Research - Trussville
Birmingham, Alabama
San Fernando Valley Health Institute
Canoga Park, California
Velocity Clinical Research, Huntington Park
Huntington Park, California
Velocity Clinical Research, San Diego
La Mesa, California
Clinical Trials Research
Lincoln, California
Velocity Clinical Research, Westlake
Los Angeles, California
Catalina Research Institute, LLC
Montclair, California
Velocity Clinical Research, North Hollywood
North Hollywood, California
Velocity Clinical Research, Panorama City
Panorama City, California
Western University of Health Sciences
Pomona, California
Velocity Clinical Research, Santa Ana
Santa Ana, California
New England Research Associates, LLC
Bridgeport, Connecticut
Excel Medical Clinical Trials
Boca Raton, Florida
Alliance for Multispecialty Research, LLC
Coral Gables, Florida
South Florida Clinical Research Institute
Margate, Florida
Emory University School of Medicine- Grady Campus
Atlanta, Georgia
Center for Advanced Research & Education
Gainesville, Georgia
Qualmedica Research, LLC
Evansville, Indiana
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa
Qualmedica Research
Bowling Green, Kentucky
NECCR PrimaCare Research
Fall River, Massachusetts
SKY Integrative Medical Center/SKYCRNG
Ridgeland, Mississippi
StudyMetrix Research
City of Saint Peters, Missouri
Clinvest Research LLC
Springfield, Missouri
Research Foundation of SUNY - University of Buffalo
Buffalo, New York
Lucas Research, Inc
Morehead City, North Carolina
The Corvallis Clinic, P.C.
Corvallis, Oregon
Clinical Research of Philadelphia
Philadelphia, Pennsylvania
Preferred Primary Care Physicians
Uniontown, Pennsylvania
Tribe Clinical Research, LLC
Greenville, South Carolina
Velocity Clinical Research, Spartanburg
Spartanburg, South Carolina
Dallas Diabetes Research Center
Dallas, Texas
CIAD Moron
Morón, Buenos Air, Argentina
Centro de Investigaciones Metabólicas (CINME)
Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata
Mar del Plata, Buenos Aires, Argentina
Go Centro Medico San Nicolás
San Nicolás de los Arroyos, Buenos Aires, Argentina
Centro Médico Viamonte
Buenos Aires, Ciudad Aut, Argentina
Dr. M.B. Jones Inc.
Victoria, British Columbia, Canada
Bluewater Clinical Research Group Inc.
Sarnia, Ontario, Canada
Stouffville Medical Centre
Stouffville, Ontario, Canada
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.